Navigation Links
Ganeden Biotech Obtains Self-Affirmed GRAS Status for Probiotic Ingredient, GanedenBC30 (Bacillus coagulans GBI-30, 6086)
Date:12/4/2007

CLEVELAND, Dec. 4 /PRNewswire/ -- An independent panel of scientists has awarded Ganeden Biotech, Inc. self-affirmed GRAS (Generally Recognized as Safe) status for its patented probiotic, GanedenBC30 (Bacillus coagulans GBI- 30, 6086). After an extensive evaluation of research studies and toxicology data, the panel concluded that GanedenBC30 is safe for use as an ingredient in food products. According to the FDA, self-affirmed GRAS status is awarded to any substance that is generally recognized among qualified experts as having been adequately shown to be safe under the conditions of its intended use.

(Logo: http://www.newscom.com/cgi-bin/prnh/20041213/CLM031LOGO )

"With so many health benefits and potential applications available for GanedenBC30, licensing partners now have one more level of confidence in the safety of GanedenBC30 as an ingredient," commented Ganeden's Founder and Chief Scientist, Sean Farmer. "Achieving GRAS status further supports our commitment to provide superior probiotic bacteria in widely available premium products," Farmer said.

GanedenBC30 (Bacillus coagulans GBI-30, 6086) is a high-survivability strain of the probiotic, Bacillus coagulans. In addition to food products, GanedenBC30 is currently used in a broad range of applications including dietary supplements, animal health products, feminine hygiene and topical applications. The probiotic cells in GanedenBC30 are able to survive very harsh manufacturing processes, do not require refrigeration and survive gastric acidity. Overall, GanedenBC30 has shown to be heartier than other probiotic strains and exhibits excellent stability, offering more flexibility in manufacturing and delivery systems.

"GanedenBC30 is different from other traditional bacteria because it is surrounded by a natural organic layer that serves as a protective shield against the manufacturing process, shelf life and stomach acids and intestinal bile," explains Farmer. "Because of this unique make-up, GanedenBC30 survives the hostile environment of the stomach, colonizes the intestines, and produces lactic acid, which are all critical factors to the success of a probiotic. That's why we initially chose a strain of Bacillus coagulans over other conventional probiotic strains," explained Farmer.

About Ganeden Labs

Established in 2006, Ganeden Labs is the licensing and development division of Ganeden Biotech, making proprietary, patented probiotic technology available for use in innovative products in a wide range of industries. Ganeden maintains an extensive intellectual property portfolio with patent and trademark protection for an array of technologies all over the world. GanedenBC30 and its related patents are available for license in a wide variety of applications. For more information, visit http://www.ganedenlabs.com.

About Ganeden Biotech

Founded in 1997, Ganeden Biotech Inc. is a consumer healthcare company based in Cleveland, Ohio that features a popular line of over-the-counter, products under the brand names Sustenex, Digestive Advantage, and Clearly Confident. Ganeden's oral products including Sustenex and Digestive Advantage contain GanedenBC30, a patented strain of Bacillus coagulans.


'/>"/>
SOURCE Ganeden Biotech
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
3. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... The Blavatnik Family Foundation and the ... of the 2017 Blavatnik Regional Awards for Young Scientists. Established in 2007, ... the New York Academy of Sciences to honor the excellence of outstanding postdoctoral ...
(Date:10/12/2017)... CA (PRWEB) , ... October ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically designed ... bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who made ...
(Date:10/11/2017)... Md. (PRWEB) , ... October 11, 2017 , ... ... digital pathology, announced today it will be hosting a Webinar titled, “Pathology is ... Advanced Pathology Associates , on digital pathology adoption best practices and how Proscia ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
Breaking Biology Technology:
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
(Date:3/29/2017)... CHICAGO , March 29, 2017  higi, the ... ecosystem in North America , today ... Partners and the acquisition of EveryMove. The new investment ... extensive set of tools to transform population health activities ... and lifestyle data. higi collects and secures ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... to 2025" report to their offering. ... The Global Biometric Vehicle Access System Market ... the next decade to reach approximately $1,580 million by 2025. ... for all the given segments on global as well as regional ...
Breaking Biology News(10 mins):